Precision BioSciences Reports Strong Q1 Results, Significant Revenue Growth, and Key Pipeline Advancements

summarizeSummary

Precision BioSciences reported significantly increased Q1 revenue, a reduced net loss, and reaffirmed its cash runway through 2028, alongside multiple positive clinical and regulatory advancements for its gene-editing programs.

check_boxKey Events

• Strong Q1 Financial Performance

  Total revenues for the first quarter ended March 31, 2026, surged to $10.8 million, a significant increase from less than $0.1 million in the prior year. The net loss improved to $18.4 million, or $(0.75) per share, compared to $20.6 million, or $(2.21) per share, in Q1 2025.

• Extended Cash Runway Confirmed

  The company reported a cash balance of $125.8 million as of March 31, 2026, and expects its existing cash, along with operational discipline and its ATM facility, to fund operations and key data milestones through 2028.

• Key Clinical Pipeline Advancements

  PBGENE-HBV advanced into new cohorts in the ELIMINATE-B trial, with late-breaking poster data showing 'first evidence of elimination and inactivation of cccDNA' accepted for EASL 2026. PBGENE-DMD received FDA IND clearance and Fast Track designation, with the first clinical trial site activated and enrolling patients for the FUNCTION-DMD trial.

• Material Partner Milestone Payment

  Precision BioSciences received a $7.5 million clinical milestone payment from TG Therapeutics, Inc., comprising $5.25 million in cash and $2.25 million for the purchase of Precision common stock.

auto_awesomeAnalysis

Precision BioSciences delivered a strong first quarter, marked by a substantial increase in revenue and a reduced net loss, signaling improved financial health. The reaffirmation of a cash runway through 2028 is a critical de-risking factor for a clinical-stage biotech, providing stability for its ambitious gene-editing programs. Significant progress across its wholly-owned pipeline, including positive clinical data for PBGENE-HBV and advancement of PBGENE-DMD into patient enrollment, demonstrates strong operational execution. Furthermore, a material milestone payment from a key partner underscores external validation and provides additional capital, collectively positioning the company favorably for upcoming data readouts and continued development.